SECsense Logo

Immunic, Inc. 8-K Report: Key Insights & Corporate Changes (January 2025)

$IMUX
Form 8-K
Filed on: 2025-01-13
Source
Immunic, Inc. 8-K Report: Key Insights & Corporate Changes (January 2025)

Based on the provided section of the financial report, here are the key pieces of information extracted:

  1. Entity Information:
  • Company Name: Immunic, Inc.
  • CIK (Central Index Key): 0001280776
  • SEC File Number: 001-36201
  • EIN (Employer Identification Number): 56-2358443
  • Address: 1200 Avenue of the Americas, Suite 200, New York, NY 10036, US
  • Contact Number: (332) 255-9818
  • Stock Exchange: NASDAQ
  1. Report Type and Date:
  • Report Type: 8-K (a report of unscheduled material events or corporate changes)
  • Filing Date: January 13, 2025
  1. Financial Context:
  • Reporting Date: January 13, 2025
  • Currency: USD (US Dollars)
  • Stock Class: Common Stock
  • Par Value: $0.0001
  1. Measurement Units:
  • The report mentions a unit of measurement in USD and shares, indicating financial metrics may be expressed in terms of monetary value per share.

Insights:

  • Nature of the Filing: The 8-K filing indicates that Immunic, Inc. is reporting a specific event that could be significant to investors, which may include changes in management, financial performance, or other critical developments.
  • Market Presence: Being listed on NASDAQ signifies that Immunic, Inc. is a publicly traded company, which enhances its visibility and credibility in the market.
  • Low Par Value: The common stock's par value of $0.0001 suggests a potentially high number of outstanding shares, which is common in biotech sectors where companies may issue many shares to raise capital.
  • Future Financial Reporting: The use of XBRL (eXtensible Business Reporting Language) indicates the company’s commitment to providing detailed and structured financial information, which could facilitate better analysis and transparency for investors.

This summary provides a snapshot of Immunic, Inc.'s recent filing, highlighting essential corporate and financial details that may be relevant for stakeholders and analysts monitoring the company's performance and compliance with SEC regulations.